HomepageCZMWY • OTCMKTS
add
Carl Zeiss Meditec
Vorige slotkoers
$Â 67,73
Dag-range
$Â 64,91 - $Â 66,23
Jaar-range
$Â 46,13 - $Â 100,31
Beurswaarde
5,21Â mld. EUR
Gem. volume
1,80K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (EUR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 560,02Â mln. | 18,62% |
Bedrijfskosten | 230,55Â mln. | 22,90% |
Netto inkomsten | 45,33Â mln. | -2,47% |
Netto winstmarge | 8,09 | -17,78% |
Winst per aandeel | 0,58 | 32,60% |
EBITDA | 100,90Â mln. | 19,78% |
Effectief belastingtarief | 30,21% | — |
Balans
Totale activa
Totale passiva
| (EUR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 26,55Â mln. | 73,09% |
Totale activa | 3,47Â mld. | 18,98% |
Totale passiva | 1,38Â mld. | 70,31% |
Totaal aandelenvermogen | 2,09 mld. | — |
Uitstaande aandelen | 87,18 mln. | — |
Koers-boekwaardeverhouding | 2,84 | — |
Rendement op activa | — | — |
Rendement op kapitaal | 6,72% | — |
Kasstroom
Nettomutatie in liquide middelen
| (EUR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 45,33Â mln. | -2,47% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Carl Zeiss Meditec AG is a multinational medical technology company and subsidiary of Carl Zeiss AG. It manufactures tools for eye examinations and medical lasers as well as solutions for neurosurgery, dentistry, gynecology and oncology. Among its products are the most common tools used by ophthalmologists and optometrists.
In October 2018, Carl Zeiss Meditec won FDA premarket approval for its ReLEx Smile laser system.
Also in October 2018, Carl Zeiss Meditec announced the acquisition of Reno, Nevada-based IanTech for an undisclosed sum.
In September 2019, Carl Zeiss Meditec launched the CIRRUS 6000 at the European Society of Retina Specialists 2019 Congress. Wikipedia
CEO
Opgericht
2002
Hoofdvestiging
Werknemers
5.713
